Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sedana Medical publishes its Annual Report for 2019

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announce that its Annual Report for 2019 has been published and is available on www.sedanamedical.com under Investors.For additional information, please contact:Christer Ahlberg, vd, Sedana Medical ABMobil: +46 70 675 33 30E-post: christer.ahlberg@sedanamedical.comMaria Engström, CFOMobile: +46 70 674 33 30E-mail: maria.engstrom@sedanamedical.com Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

Revenio Group Corporation: Interim Report, January 1 - March 31, 2020

Revenio Group Corporation, Stock Exchange Release, April 22, 2020 at 9.00 amRevenio Group Corporation: Interim report January 1–March 31, 2020 Figures in brackets refer to the same period in the previous year, unless otherwise stated. Reasonable quarter; effects of the COVID-19 pandemic began to appear towards the end of the quarter January–March 2020 · Net sales totaled EUR 11.9 (8.4) million, up 41.5% · Operating profit was EUR 2.4 (2.6) million, down 5.8% · EBITDA was EUR 3.1 (2.9) million, up 7.4% · The currency-adjusted growth of net sales in January–March was 40.

Annual General Meeting in Oncopeptides AB (publ)

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden, Tuesday 26 May 2020 at 2.00 p.m. Registration for attendees will commence at 1.30 p.m. Due to the current pandemic (COVID-19), Oncopeptides has taken a number of precautionary measures ahead of the Annual General Meeting aimed at keeping the meeting short and efficient and reduce the risk of

Correction of reference in announced press release

Polygon AB (publ) has yesterday April 21, 2020 at 16:00 CEST issued a press release regarding the publication of its Annual Report for 2019.The press release incorrectly referred to the information being published pursuant to the EU Market Abuse Regulation, whereas the correct reference should have been that the information was published pursuant to the Swedish Securities Market Act. Accordingly, for the avoidance of doubt, the company did not consider any information in the Annual Report or the press release to constitute inside information under the EU Market Abuse Regulation.

Outokumpu – Publishing of the first-quarter 2020 results

Outokumpu OyjPress releaseApril 22, 2020 at 9.00 am EESTOutokumpu – Publishing of the first-quarter 2020 results Outokumpu will publish the first-quarter 2020 results on Wednesday, May 6, 2020 at approximately 9.00 am EEST. A conference call for investors and analysts will be held on Wednesday, May 6, 2020 at 3.00 pm EEST (8.00 am US EST, 1.00 pm UK, 2.00 pm CET). The results call will be hosted by Outokumpu’s CEO Roeland Baan and CFO Pia Aaltonen-Forsell. To participate in the conference call, please dial in 10−15 minutes before the beginning of the event: Finland: +358 9 4245

Getinge Interim Report for January-March 2020: Intense efforts to help hospitals in the COVID-19 pandemic

“The quarter was dominated by the COVID-19 pandemic and the huge need for advanced ventilators and ECMO therapy at intensive care units around the world. Our leading global positions in these fields contributed to a 47% organic order growth, says Mattias Perjos, President & CEO Getinge. “We expect to see continuing strong demand in both areas since demand is far outstripping supply”. Consequently, Getinge announced at the start of April an increased production capacity of ventilators by 160% compared with 2019. Getinge expects the high delivery rate to continue into 2021 and

Interim report January–March 2020

Quote from Therese Hillman, Group CEO “To further strengthen competitiveness and increase efficiency, we initiated a full integration with Red Tiger during the quarter. Red Tiger keeps performing above our expectations with its award-winning games and the expansion to new markets continues. Combined with a strong product pipeline, new regulated market entries and the Live Casino opportunity for NetEnt, this puts us in a good position to continue delivering profitable growth in 2020.” First quarter of 2020  · Revenues for the first quarter amounted to 518 (418) SEKm · EBITDA was

Edogawa Hospital first in Japan to order Elekta Unity MR-Linac

Cutting-edge technology to address need for treating cancer with greatest precisionTOKYO, April 22, 2020 – People living with cancer in Japan will have access to the most technically advanced radiotherapy treatment available as Edogawa Hospital acquires an Elekta Unity MR-Linac system. Elekta Unity gives doctors the “vision” to zero in on tumors and avoid healthy tissues and thereby addresses an unmet need in cancer therapy – it will enable Edogawa Hospital’s clinicians to confidently see and track the target during treatment and respond accordingly, and to adapt the treatment plan daily to

Invitation to SRV Group Plc’s January – March 2020 interim report audiocast and conference call

SRV GROUP PLC     INVESTOR NEWS     22 APRIL 2020      8.30 EET Invitation to SRV Group Plc’s January – March 2020 interim report audiocast and conference call SRV Group Plc will publish January – March 2020 interim report on Wednesday 29 April 2020 at 8.30 EET. The report can be found on the company's website www.srv.fi/en/investors. SRV will present the financial result to the analysts, fund managers, investors and representatives of the media at a combined audiocast and conference call on the same day starting at 12.00 EET. The event will be held in Finnish and hosted by CEO

SpareBank 1 SR-Bank ASA (SRBANK): Increased loan impairments and reduced financial income

In connection with the presentation of its results for the fourth quarter of 2019, SpareBank 1 SR-Bank ASA stated that its return on equity after tax target for the financial year 2020 was 12%. At the time, the Norwegian economy was virtually unaffected by the Covid-19 situation. As a result of the significant consequences in connection of the partial lockdown of society, combined with the substantial fall in oil prices, the marked downturn in activity has resulted in uncertainty and weaker profitability for many of our customers. SpareBank 1 SR-Bank ASA is a solid bank and at the end

Opus revises its financial targets 2020

Opus’ established financial targets from April 2019 have been revised by the Board.Following the acquisition of a majority stake of Opus by Ograi and the improved headroom with respect to the leverage covenant under the new financing from Ares, the Opus Board of Directors has decided to remove the leverage target as of 2020. The financial targets for revenue growth and EBITA margin, adopted by the Board in early 2019, remain unchanged. The 2020 targets are as follows: · 5-10% annual revenue growth (Organic and acquisitive growth based on 3-year CAGR) · 15% EBITA margin

Zengun Group AB 2019 Annual General Meeting

At the Zengun Group AB Annual General Meeting, held on 21 April 2020, it was resolved that the board should comprise five members, without deputies. Board members Jan Örnevik, Ulf Jonsson, Henrik Lif, Cecilia Safae and Tobias Örnevik were re-elected. Jan Örnevik was re-elected Chairman of the Board. The proposed appropriation of profits was approved and the meeting resolved that the profit for the year be carried forward. The meeting resolved that the remuneration to the Board of Directors should remain unchanged at SEK 160,000 per member, including the Chairman of the Board.

The Zengun Group Annual Report for 2019 is now published

The Annual Report 2019 for Zengun Group AB is now available in Swedish and English language versions at the company website as a pdf-document. Please visit www.zengun.se.  For more information, please contact: Sture Nilsson, VD och koncernchef +46 (0)70 580 04 15Anna-Carin Bjelkeby, Ekonomi- och finansdirektör +46 (0) 70 580 62 25 Prior to publication, this information constituted insider information. This information is of such a kind that Zengun Group AB (publ) is legally required to disclose pursuant to the EU’s Market Abuse Regulation. This information was submitted through

Elisa’s Interim Report Q1 2020

ELISA CORPORATION INTERIM REPORT RELEASE 22 APRIL 2020 AT 8:30 AMFirst quarter 2020 financial highlights •    Revenue increased by EUR 28m to EUR 468m, mainly due to Polystar acquisition.•    Mobile service revenue increased by 2.1 per cent to EUR 208m. •    Comparable EBITDA grew by EUR 8m to EUR 166m. •    Comparable EBIT increased by EUR 7m to EUR 99m.•    Cash flow grew by EUR 5m to EUR 73m, mainly due to growth in EBITDA. •    Mobile post-paid ARPU was at the previous quarter’s level EUR 19.3 (19.3).•    Mobile post-paid churn decreased to 18.9 per cent (20.1 in previous

Konftel Achieves Climate Neutral Certification

Swedish-based Konftel, a global leader in products for effective distance meetings, has successfully achieved Climate Neutral Certified status. It means customers choosing their conference products will start at zero in carbon footprint when substituting business travel with online meetings.Climate Neutral Certified is a new trusted standard founded by the non-profit organization Climate Neutral. Konftel got the certificate by measuring its 2019 greenhouse gas emissions footprint, purchasing carbon credits to offset that footprint, and implementing plans to reduce emissions this year and

Ericsson reports first quarter results 2020

First quarter highlights · Sales were SEK 49.8 (48.9) b. A decline by -2% adjusted for comparable units and currency. · The Covid-19 pandemic had limited impact on operating income and cash flow in the quarter. · Gross margin excluding restructuring charges improved to 40.4% (38.5%). Gross margin improved QoQ in all segments. · Operating income excluding restructuring charges was SEK 4.6 b. (9.3% operating margin). Q1 2019 operating income excluding restructuring charges and items affecting comparability was SEK 3.5 b. (7.2% operating margin). · Networks sales adjusted for

Atea reports financial results for Q1 2020

Atea, the leading supplier of IT infrastructure products and services in the Nordic and Baltic regions, today reported its interim financial results for the first quarter of 2020.  Revenue was approximately in line with last year, despite a challenging market environment. Atea’s revenue in Q1 2020 was NOK 9,043 million, a decrease of 1.0% from last year. Hardware revenue was down 7.4%, while software revenue was up 6.7% and services revenue was up 5.7% from last year. EBIT before restructuring costs were NOK 103 million, a decrease of 10.9% from last year. As previously announced in

Growth and higher profitability

Axfood reports a strong first quarter with continued high growth and improved profitability. This at the same time that the company is in a tumultuous and exceptional period – a situation in which the food industry has an important and societally essential role in providing the entire country with food and groceries. The novel coronavirus, COVID-19, has had and will continue to have a major impact on society and thus also on the company’s operations.President and CEO Klas Balkow’s comments on the interim report for the first quarter 2020: “The first quarter of this year was a very

Handelsbanken’s Interim Report January - March 2020

Summary January - March 2020, compared with January - March 2019 · Strong capital situation and liquidity. The common equity tier 1 ratio increased to 17.6% (16.4).  · Stable credit quality. The credit loss ratio was 0.08% (0.05). 0.07% of this amount was attributable to additional provision requirements for expected credit losses.  · Operating profit went down by 16% to SEK 5,142m (6,110). Adjusted for foreign exchange effects and the reversal of 2018’s preliminary provision for the Oktogonen profit-sharing scheme carried out during the period of comparison, operating profit

Solid underwriting result offset by effects from financial market turmoil

The first quarter of 2020 was characterised by a solid underwriting result driven by effective pricing measures and strong profitability. The Covid-19 situation had a limited impact on the underwriting result. However, the investment portfolio was hit by the general turmoil in the financial markets. The Group’s long-term outlook remains good, but with considerable short-term uncertainty on the investment side. The Board has resolved to withdraw the dividend proposal in response to regulatory stance. It is the Board’s intention to distribute dividends to shareholders as soon as the situation

INTERIM REPORT FOR THE FIRST QUARTER 2020 NEW WAVE GROUP AB

PERIOD 1 JANUARY – 31 MARCH 2020 · Net sales amounted to SEK 1,440.9 million, which was 4 % (7 % in local currencies) lower than last year (SEK 1,504.9 million). · Operating result amounted to SEK -24.1 (46.0) million. · Result for the period amounted to SEK -36.9 (26.0) million. · Earnings per share amounted to SEK -0.54 (0.41). · Cash flow from operating activities amounted to SEK 114.6 (-65.1) million. · Equity ratio amounted to 46.8 (45.9) %. · Net debt to equity ratio amounted to 74.6 (73.7) %. CEO COMMENTS The year started strongly with good earnings

Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology

· Targovax and Valo Therapeutics intend to run pre-clinical proof-of-concept studies testing mutant RAS peptide coated ONCOS-102 adenovirus · If successful, the collaboration could lead to further development of a first-in-class mutant-RAS targeting oncolytic virus Oslo, Norway, & Helsinki, Finland 22 April 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses and cancer vaccines to target hard-to-treat solid tumors, and Valo Therapeutics (Valo Tx) today announce that they have entered into a collaboration agreement to evaluate PeptiCRAd

Telia Company Interim report January-March 2020

SERVICE REVENUE TREND IMPROVED SEQUENTIALLYFirst quarter summary · Net sales rose 7.6 percent to SEK 22,427 million (20,836) and like for like regarding exchange rates, acquisitions and disposals, net sales fell 2.2 percent. · Service revenues grew 10.5 percent to SEK 19,716 (17,836) and like for like regarding exchange rates, acquisitions and disposals, service revenues declined 1.0 percent. · Adjusted EBITDA fell 1.8 percent to SEK 7,277 million (7,413) and the adjusted EBITDA margin fell to 32.4 percent (35.6). Like for like regarding exchange rates, acquisitions and disposals,

Resolution on purchases of own shares by Axfood’s Board of Directors

The Board of Directors of Axfood has decided to exercise the authorization granted to it by the Annual General Meeting on 18 March 2020 to purchase own shares. At the time of publication of this press release Axfood owns 572,000 treasury shares, corresponding to 0.3% of the total number of shares.Purchases may take place on one or more occasions during the period 18 May 2020 until the next Annual General Meeting of a maximum of 310,000 shares. Purchases shall be made on Nasdaq Stockholm at a price per share that is within the registered price interval at any given time, i.e., the interval

There are no items matching the current filter
There are no more items matching the current filter
Back to top